Product Description

Indications: Ornopain is indicated for the short-term relief of acute mild to moderate pain, symptomatic relief of pain and inflammation associated with osteoarthritis, and symptomatic relief of pain and inflammation in rheumatoid arthritis.Pharmacology: Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) and antirheumatic agent belonging to the oxicam class. It is used for short-term management of acute pain and inflammatory joint disorders such as osteoarthritis and rheumatoid arthritis. Its mechanism of action mainly involves inhibition of cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis, decreased inflammation, and reduced sensitization of peripheral pain receptors.Dosage & Administration: For acute pain, the recommended daily dose is 8-16 mg divided into 2 or 3 doses, with a maximum daily dose of 16 mg. For osteoarthritis and rheumatoid arthritis, the initial recommended dose is 12 mg daily divided into 2 or 3 doses, and the maintenance dose should not exceed 16 mg daily. In patients with mild to moderate renal impairment or moderate hepatic impairment, the maximum recommended daily dose is 12 mg divided into 2 or 3 doses. Elderly patients generally do not require dose adjustment, although caution is advised due to increased sensitivity to gastrointestinal adverse effects. Lornoxicam is not recommended for children and adolescents below 18 years of age.Interaction: Concomitant use with vitamin K antagonists such as warfarin may increase the risk of bleeding. Co-administration with cyclosporine may increase the risk of kidney dysfunction and acute renal injury. Lornoxicam may increase the adverse effects of lithium, methotrexate, digoxin, and related drugs. It may also reduce the effectiveness of diuretics, ACE inhibitors, and angiotensin II receptor antagonists, particularly in patients with heart failure.Contraindications: Ornopain is contraindicated in patients with hypersensitivity to lornoxicam or any formulation components, active peptic ulcer disease, severe hepatic impairment, severe renal impairment, thrombocytopenia, and during the third trimester of pregnancy.Side Effects: Common adverse effects are mainly gastrointestinal and may include nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, flatulence, gastrointestinal bleeding, peptic ulcer, melaena, hematemesis, ulcerative stomatitis, and worsening of colitis or Crohn’s disease. Severe gastrointestinal complications may occur, especially in elderly patients.Pregnancy & Lactation: Lornoxicam is contraindicated during the third trimester of pregnancy and should generally be avoided during pregnancy due to insufficient safety data. It is excreted into breast milk in animal studies; therefore, it should not be used during breastfeeding.Precautions & Warnings: Caution is advised in patients with impaired renal function, hypertension, heart failure, ulcerative colitis, Crohn’s disease, asthma, bleeding disorders, systemic lupus erythematosus (SLE), and in women undergoing infertility treatment. The lowest effective dose should be used for the shortest duration necessary to minimize adverse effects.Overdose Effects: Symptoms of overdose may include nausea, vomiting, dizziness, and visual disturbances. In suspected overdose, the medication should be discontinued and supportive treatment initiated. Gastric lavage may be considered if appropriate. Lornoxicam is not dialyzable and no specific antidote is available.Therapeutic Class: Non-steroidal Anti-inflammatory Drugs (NSAIDs).Storage Conditions: Store below 30°C in a dry place protected from light and moisture. Keep out of reach of children.